DREAM3R
07 Dec 2020
Trial Summary
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)
Acronym:
DREAM3R
ACTRN/NCT /ethics:
NCT04334759
Scientific title:
DuRvalumab with chEmotherapy vs chemotherapy alone as first line treAtment in advanced, pleural Mesothelioma – a phase 3 Randomised trial
Sponsor / Cooperative group:
PrECOG, LLC.
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2020-09-01 |
| Anticipated End Date | 2025-05-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Rachel Roberts-Thomson |
| Recruitment Status | Not Yet Recruiting |